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Previewsof tanycytes in delivering signals through
other circumventricular organs such as
the area postrema? Do tanycytes regulate
the transport of other signals such as
ghrelin or nutrients? What role do tany-
cytes play in other mechanisms that
have been described to promote leptin
resistance such as ER stress, inflamma-
tion, or nutrient overload (Banks et al.,
2004; Milanski et al., 2009; Ozcan et al.,
2009)?
Finally, once their function as hypo-
thalamic gatekeepers is established the
question remains whether tanycytes are
amenable like Portunes, allowing targeted
pharmacology to manipulate leptin entry,or more like Cerberus, refusing any
negotiation.
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Macrophages in atherosclerotic plaques are activated, inflammatory cells that directly contribute to the
disease process. De Nardo et al. (2013), now report that high-density lipoproteins (HDL) can reprogram
macrophages to be less inflammatory through an ATF3-dependent pathway, providing another mechanistic
basis for the atheroprotective properties of HDL.Atherosclerosis is commonly referred
to as an inflammatory disease. The key
player in the early phase of inflammation
in plaques is the foot soldier of the innate
immune system, the macrophage. These
cells become activated in the arterial
wall in response to uptake of lipoproteins
containing apolipoprotein B, such as
low- and very-low-density lipoproteins
(LDLs and VLDLs) (Tabas et al., 2007).
The cholesterol carried by these lipopro-
teins causes themacrophages to become
engorged ‘‘foam cells,’’ which become
trapped in the arterial intima, establishing
the inflammatory milieu of the plaque. The
failure to resolve this inflammation is
thought to culminate in ‘‘vulnerable’’
atherosclerotic plaques, which are prone
to rupture, leading to heart attacks and
strokes. Inflammatory mediators (IL-1b,
TNFa, and MCP-1, etc.) secreted by
macrophage foam cells following thestimulation of innate immune receptors
such as Toll-like receptors (TLR), or via in-
flammasome pathways, have adverse
effects on the other two major cell types
in the plaques, endothelial and vascular
smooth muscle cells. Furthermore, dying
macrophage foam cells contribute to
the formation of the necrotic core, which
is enriched in cholesterol, inflammatory
substances, and thrombogenic Tissue
Factor and is a hallmark of vulnerable
plaques. Thus, factors that either impede
the escalating inflammation process or
reverse it may make it possible to derail
the march to a clinical event. It is in this
context that the studies by Latz and col-
leagues fall, by showing how HDL may
be a fire prevention or extinguishing agent
through stimulating an anti-inflammatory
pathway in macrophages that is depen-
dent on the transcription factor ATF3
(De Nardo et al., 2013).De Nardo et al. began by investigating
the effects of HDL on the activation of
macrophages by TLRs in vitro. First, they
confirmed previous studies (e.g., Yvan-
Charvet et al., 2008) showing that HDL
treatment reduced the inflammatory
responsiveness of the macrophages to
TLR stimulation. For this purpose, they
focused on TLR1, TLR2, and TLR9 (cho-
sen because they had been implicated in
previous studies in atherosclerotic mice),
using accepted ligands for each. They
found that the anti-inflammatory effects
of HDL were independent of HDL binding
of TLR ligands and did not involve the
classical early signaling downstream of
the TLRs. They also found in contrast
to Yvan-Charvet et al. (2008) that there
was no evidence that the impaired
TLR responsiveness resulted from HDL-
mediated depletion of cholesterol from
plasma and endosomal membranes., February 4, 2014 ª2014 Elsevier Inc. 175
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PreviewsAlthough different TLRs were investigated
in the two studies, each used ligands to
activate TLR signaling at both the cell
surface (TLR2 and TLR4) and intracellu-
larly (TLR3 and TLR9), so this cannot
explain the divergent outcomes. One pos-
sibility for this discrepancy could be the
lack of the cholesterol efflux factors
ABCA1 and ABCG1 in the experimental
system of the previous study, resulting
in altered membrane lipid composition
and microenvironments.
Still searching for an explanation for the
effects of HDL on TLR responsiveness,
De Nardo et al. turned their attention
to the decreases they noted in the
mRNAs for numerous cytokine genes,
including Il6, Il12p40, and Tnfa, sug-
gesting a transcriptional mechanism
induced by HDL. In a key experiment,
the authors performed microarray pro-
filing of HDL-treated macrophages and,
through bioinformatics analyses, identi-
fied an enrichment in genes regulated by
the transcription factor ATF3. ATF3 has
been proposed to act as a negative
regulator of transcription through its
ability to recruit corepressors, such as
histone deacetylase 1, which are thought
to promote a closed chromatin con-
formation at target gene promoters. The
authors confirmed that HDL treatment
of bone marrow-derived macrophages
increased expression of Atf3 mRNA and
protein and showed ATF3 binding at
promoters of cytokine genes down-
regulated by HDL. Finally, they used
ATF3-deficient mice to show that the
HDL-mediated suppression of inflamma-
tory mediator production was dependent
on ATF3 in vitro and in vivo. Overall, the
data support amechanism for anti-inflam-176 Cell Metabolism 19, February 4, 2014 ª2matory effects of HDL on macrophages
exposed to stimuli resembling those they
are likely to encounter in normal and dis-
ease states.
HDL is thought to dampen inflammation
in the atherosclerotic plaque via multiple
mechanisms: e.g., it reduces cellular
cholesterol levels, has antioxidant effects,
inhibits platelet aggregation, and sup-
presses the proliferation of hematopoietic
progenitor cells. In mouse models of
atherosclerosis, an increase in functional
HDL particles has been reported to
reduce the expression in plaque macro-
phages of inflammatory mediators, an
effect similar to that in De Nardo et al.,
but also to increase the expression of
markers of the anti-inflammatory M2 state
(Feig et al., 2011; Rayner et al., 2011).
Consistent with this latter effect is the
recent report that, in vitro, HDL induces
markers of the M2 state in macrophages
(Sanson et al., 2013). Although the current
study did not examine the effect of
ATF3 on plaque macrophages or M2 po-
larization, the authors did show beneficial
effects of HDL on carotid artery re-
endothelialization in hypercholesteromic
Apoe–/– mice. These protective effects
of HDL on carotid injury were driven by
ATF3-mediated reduction of macrophage
inflammation. Despite these benefits, the
resemblances between atherosclerosis
and the arterial injury model, which has
been likened to a form of accelerated
atherosclerosis, are superficial, with
many aspects varying from the authentic
disease. Thus, a more physiological test
of the impact of ATF3 and its regulation
by HDL on gene expression in macro-
phage foam cells of the atherosclerotic
plaque awaits.014 Elsevier Inc.In summary, the current study repre-
sents an important advance in the
conceptual understanding of the anti-
inflammatory effects of HDL. While the
authors note how these findings may
aid in predicting the clinical benefits of
HDL-based therapies by detailing the
mechanisms for the effects of HDL on
ATF3, it may also be possible for small
molecules or other convenient agents to
accomplish the same anti-inflammatory
effects without having to administer or
raise the number of functional HDL parti-
cles. Thus, there ultimately may be a
number of ways to harness the fire-
fighting properties of HDL, with the poten-
tial application to inflammatory diseases
beyond atherosclerosis.REFERENCES
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